Melanocortin 5 receptor signaling pathway in health and disease.
Autoimmune uveitis
Immune response
Kidney
Melanocortin
Melanocortin receptor
Muscle
Sebogenesis
Journal
Cellular and molecular life sciences : CMLS
ISSN: 1420-9071
Titre abrégé: Cell Mol Life Sci
Pays: Switzerland
ID NLM: 9705402
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
received:
22
01
2020
accepted:
24
03
2020
revised:
17
03
2020
pubmed:
6
4
2020
medline:
3
10
2020
entrez:
6
4
2020
Statut:
ppublish
Résumé
Melanocortin hormone system plays a key role in maintaining the homeostasis of our body via their neuro-immune-endocrine activities and regulates a diverse array of physiological functions, including melanogenesis, inflammation, immunomodulation, adrenocortical steroidogenesis, hemodynamics, natriuresis, energy homeostasis, sexual function, and exocrine secretion. The pathobiologic actions of all melanocortins are conveyed by melanocortin receptors. As the last melanocortin receptor to be cloned and characterized, melanocortin receptor 5 (MC5R) is widely expressed in both central nervous system and a number of peripheral organ systems in man. However, the exact effect of the MC5R mediated melanocortinergic signaling remains largely uncertain. Owing to the recent advances in developing highly selective peptidomimetic agonists and antagonists of MC5R and also to studies in MC5R knockout animals, our understanding of MC5R pathobiology has been greatly expanded and strengthened. Evidence suggests that MC5R plays a key role in governing immune reaction and inflammatory response, and is pivotal for the regulation of sexual behavior, thermoregulation, and exocrine secretion, like sebogenesis, lacrimal secretion and release of sex pheromones. As such, recent translational efforts have focused on developing novel sebum-suppressive therapies for seborrhoea and acne vulgaris based on antagonizing MC5R. Conversely, selective MC5R agonists have demonstrated promising beneficial effects in immune-mediated diseases, metabolic endocrinopathies and other disease conditions, such as glomerular diseases and dry eyes, skin and mouth. Thus, MC5R-mediated signaling is essential for health. Therapeutic targeting of MC5R represents a promising and pragmatic therapeutic strategy for diverse diseases. This review article delineates the biophysiology of MC5R-mediated biophysiology of the melanocortin hormone system, discusses the existing data on MC5R-targeted therapy in experimental disease models, and envisages the translational potential for treating human diseases.
Identifiants
pubmed: 32248247
doi: 10.1007/s00018-020-03511-0
pii: 10.1007/s00018-020-03511-0
pmc: PMC7511443
mid: NIHMS1591398
doi:
Substances chimiques
Melanocortins
0
Receptors, Melanocortin
0
melanocortin 5 receptor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3831-3840Subventions
Organisme : NIDDK NIH HHS
ID : R01 DK114006
Pays : United States
Organisme : NIH HHS
ID : DK114006
Pays : United States
Organisme : NIH HHS
ID : DK114006
Pays : United States
Références
Neurosci Biobehav Rev. 1982 Fall;6(3):297-310
pubmed: 6294567
Adv Chronic Kidney Dis. 2014 Mar;21(2):134-51
pubmed: 24602463
Mol Cell Endocrinol. 2009 May 6;303(1-2):74-81
pubmed: 19428994
Biochem Biophys Res Commun. 2002 Apr 12;292(4):1075-80
pubmed: 11944925
J Med Chem. 2011 Dec 8;54(23):8078-84
pubmed: 22011200
Eur J Pharmacol. 2011 Jun 11;660(1):202-6
pubmed: 21215742
Mediators Inflamm. 2016;2016:7368389
pubmed: 26949291
Physiol Genomics. 2004 Jun 17;18(1):108-18
pubmed: 15084711
Biochim Biophys Acta. 2013 Jul;1831(7):1267-75
pubmed: 24046867
J Dermatol Sci. 2011 Jul;63(1):23-32
pubmed: 21602033
J Exp Biol. 2009 Dec;212(Pt 23):3901-10
pubmed: 19915133
Eur J Pharmacol. 2003 Feb 21;462(1-3):41-52
pubmed: 12591094
Endocr Res. 2000 Nov;26(4):537-44
pubmed: 11196426
J Invest Dermatol. 2000 Oct;115(4):614-9
pubmed: 10998132
Biochem J. 1998 Apr 1;331 ( Pt 1):211-6
pubmed: 9512481
Sci Rep. 2016 Jun 08;6:27589
pubmed: 27270328
Front Neurosci. 2015 Jun 10;9:213
pubmed: 26113808
Cytogenet Cell Genet. 1995;68(1-2):79-81
pubmed: 7956366
Mol Metab. 2016 Aug 05;5(10):807-822
pubmed: 27688995
PLoS One. 2010 Mar 23;5(3):e9837
pubmed: 20352127
Ann N Y Acad Sci. 1999 Oct 20;885:1-21
pubmed: 10816638
Metabolism. 2006 Aug;55(8):1083-7
pubmed: 16839845
J Biol Chem. 2007 Feb 2;282(5):2862-70
pubmed: 17127674
J Immunol. 2013 Oct 15;191(8):4103-11
pubmed: 24043903
Genomics. 2003 Feb;81(2):184-91
pubmed: 12620396
Int J Obes Relat Metab Disord. 1999 Feb;23(2):163-5
pubmed: 10078851
Scand J Immunol. 2005 Mar;61(3):279-84
pubmed: 15787746
Nat Rev Nephrol. 2011 Dec 06;8(2):122-8
pubmed: 22143333
Curr Drug Targets. 2003 Oct;4(7):586-97
pubmed: 14535656
Biochem Biophys Res Commun. 1994 Apr 29;200(2):1007-14
pubmed: 8179577
Immunol Cell Biol. 2001 Aug;79(4):358-67
pubmed: 11488983
Mol Cell Endocrinol. 2012 Sep 25;361(1-2):69-79
pubmed: 22871966
J Biol Chem. 1994 Dec 23;269(51):32085-91
pubmed: 7798202
J Mol Signal. 2007 Feb 26;2:2
pubmed: 17319972
Cell. 1997 Dec 12;91(6):789-98
pubmed: 9413988
Anat Embryol (Berl). 2006 Mar;211(2):109-17
pubmed: 16463171
Exp Neurol. 1999 Jun;157(2):359-65
pubmed: 10364447
PLoS One. 2015 Apr 10;10(4):e0123232
pubmed: 25860801
Ann N Y Acad Sci. 2003 Jun;994:154-61
pubmed: 12851311
Peptides. 2007 Jun;28(6):1191-6
pubmed: 17482720
BMC Res Notes. 2015 Oct 12;8:559
pubmed: 26459134
J Neurochem. 2002 Jul;82(1):6-18
pubmed: 12091460
Am J Physiol Endocrinol Metab. 2003 Mar;284(3):E468-74
pubmed: 12556347
Biochem Biophys Res Commun. 1994 May 16;200(3):1214-20
pubmed: 8185570
J Appl Genet. 2013 Nov;54(4):461-72
pubmed: 23996627
Chem Senses. 2004 Feb;29(2):111-5
pubmed: 14977807
Neuroreport. 2012 Jul 11;23(10):596-600
pubmed: 22643233
Kidney Int. 2013 Apr;83(4):635-46
pubmed: 23325074
Peptides. 2006 Feb;27(2):413-20
pubmed: 16309786
Endocr Rev. 2006 Dec;27(7):736-49
pubmed: 17077189
Front Physiol. 2018 Oct 26;9:1475
pubmed: 30416452
Gen Comp Endocrinol. 2006 Aug;148(1):85-94
pubmed: 16289182
Pharmacol Res. 2000 Nov;42(5):393-420
pubmed: 11023702
Behav Genet. 2006 Mar;36(2):291-300
pubmed: 16408249
Biochemistry. 1994 Apr 19;33(15):4543-9
pubmed: 8161509
Pharmacol Ther. 2006 Jul;111(1):1-15
pubmed: 16488018
Invest Ophthalmol Vis Sci. 2011 Nov 17;52(12):8862-7
pubmed: 21989727
Pharmacol Rev. 2004 Mar;56(1):1-29
pubmed: 15001661
Trends Pharmacol Sci. 2002 Oct;23(10):447-9
pubmed: 12368061
Mol Cell Endocrinol. 2011 Jul 20;341(1-2):9-17
pubmed: 21616121
Endocrinology. 1998 May;139(5):2348-55
pubmed: 9564844
Trends Neurosci. 2008 Jul;31(7):353-60
pubmed: 18550183
Cell Mol Biol (Noisy-le-grand). 2006 May 30;52(2):53-9
pubmed: 16914087
Front Neuroendocrinol. 2011 Jan;32(1):70-83
pubmed: 20932857
Cell Mol Life Sci. 2001 Mar;58(3):434-41
pubmed: 11315190
Biochem Biophys Res Commun. 1993 Sep 15;195(2):866-73
pubmed: 8396929
Clin Exp Dermatol. 2006 May;31(3):407-12
pubmed: 16681590